CN101068573A - 局部用奈帕芬胺制剂 - Google Patents

局部用奈帕芬胺制剂 Download PDF

Info

Publication number
CN101068573A
CN101068573A CNA200580041442XA CN200580041442A CN101068573A CN 101068573 A CN101068573 A CN 101068573A CN A200580041442X A CNA200580041442X A CN A200580041442XA CN 200580041442 A CN200580041442 A CN 200580041442A CN 101068573 A CN101068573 A CN 101068573A
Authority
CN
China
Prior art keywords
composition
mannitol
nepafenac
carbomer
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580041442XA
Other languages
English (en)
Chinese (zh)
Inventor
W·翁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35848959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101068573(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN101068573A publication Critical patent/CN101068573A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA200580041442XA 2004-12-02 2005-12-02 局部用奈帕芬胺制剂 Pending CN101068573A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63256204P 2004-12-02 2004-12-02
US60/632,562 2004-12-02

Publications (1)

Publication Number Publication Date
CN101068573A true CN101068573A (zh) 2007-11-07

Family

ID=35848959

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580041442XA Pending CN101068573A (zh) 2004-12-02 2005-12-02 局部用奈帕芬胺制剂

Country Status (23)

Country Link
US (3) US7834059B2 (cg-RX-API-DMAC7.html)
EP (1) EP1819362B1 (cg-RX-API-DMAC7.html)
JP (2) JP4968844B2 (cg-RX-API-DMAC7.html)
KR (1) KR101289661B1 (cg-RX-API-DMAC7.html)
CN (1) CN101068573A (cg-RX-API-DMAC7.html)
AR (1) AR052252A1 (cg-RX-API-DMAC7.html)
AT (1) ATE476200T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005311738B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518904B1 (cg-RX-API-DMAC7.html)
CA (1) CA2586807C (cg-RX-API-DMAC7.html)
CY (1) CY1110780T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022756D1 (cg-RX-API-DMAC7.html)
DK (1) DK1819362T3 (cg-RX-API-DMAC7.html)
ES (1) ES2348249T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007006558A (cg-RX-API-DMAC7.html)
PL (1) PL1819362T3 (cg-RX-API-DMAC7.html)
PT (1) PT1819362E (cg-RX-API-DMAC7.html)
RU (1) RU2007124638A (cg-RX-API-DMAC7.html)
SI (1) SI1819362T1 (cg-RX-API-DMAC7.html)
TW (1) TWI358290B (cg-RX-API-DMAC7.html)
UY (1) UY29238A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006060618A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704763B (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104490861A (zh) * 2014-11-21 2015-04-08 三明欣茂药业有限公司 一种缓释型奈帕芬胺眼用制剂
CN106963730A (zh) * 2016-12-22 2017-07-21 广州仁恒医药科技股份有限公司 高度稳定的奈帕芬胺眼用药物组合物
CN107024550A (zh) * 2016-12-21 2017-08-08 广州仁恒医药科技股份有限公司 奈帕芬胺眼用药物组合物的质控方法
CN111568906A (zh) * 2019-02-15 2020-08-25 诺华股份有限公司 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品
CN113573738A (zh) * 2019-01-14 2021-10-29 麦迪维斯有限责任公司 基于奈帕芬胺的化学和物理稳定的局部眼科制剂

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
AU2006244245B2 (en) * 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
CN101754748A (zh) * 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
TWI531362B (zh) * 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
CN105362221A (zh) * 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
HUE038821T2 (hu) 2009-12-03 2018-11-28 Novartis Ag Karboxivinil polimert tartalmazó nanorészecske szuszpenziók
US9544143B2 (en) 2010-03-03 2017-01-10 Duo Security, Inc. System and method of notifying mobile devices to complete transactions
US9532222B2 (en) 2010-03-03 2016-12-27 Duo Security, Inc. System and method of notifying mobile devices to complete transactions after additional agent verification
US9467463B2 (en) 2011-09-02 2016-10-11 Duo Security, Inc. System and method for assessing vulnerability of a mobile device
CN104114154A (zh) * 2011-12-16 2014-10-22 阿勒根公司 包含聚乙烯基己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus)的眼用组合物
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
HUE048564T2 (hu) 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
US9930060B2 (en) 2015-06-01 2018-03-27 Duo Security, Inc. Method for enforcing endpoint health standards
US10412113B2 (en) 2017-12-08 2019-09-10 Duo Security, Inc. Systems and methods for intelligently configuring computer security
US11658962B2 (en) 2018-12-07 2023-05-23 Cisco Technology, Inc. Systems and methods of push-based verification of a transaction
CN114272207B (zh) * 2022-01-21 2023-04-11 山东诺明康药物研究院有限公司 一种纳米晶混悬滴眼液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (cg-RX-API-DMAC7.html) 1967-07-31 1971-03-24
CH577461A5 (cg-RX-API-DMAC7.html) 1975-08-13 1976-07-15 Robins Co Inc A H
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
EP0195582B1 (en) 1985-03-14 1990-01-24 SMITH KLINE DAUELSBERG GmbH 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104490861A (zh) * 2014-11-21 2015-04-08 三明欣茂药业有限公司 一种缓释型奈帕芬胺眼用制剂
CN107024550A (zh) * 2016-12-21 2017-08-08 广州仁恒医药科技股份有限公司 奈帕芬胺眼用药物组合物的质控方法
CN106963730A (zh) * 2016-12-22 2017-07-21 广州仁恒医药科技股份有限公司 高度稳定的奈帕芬胺眼用药物组合物
CN113573738A (zh) * 2019-01-14 2021-10-29 麦迪维斯有限责任公司 基于奈帕芬胺的化学和物理稳定的局部眼科制剂
CN111568906A (zh) * 2019-02-15 2020-08-25 诺华股份有限公司 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品
CN111568906B (zh) * 2019-02-15 2023-09-01 诺华股份有限公司 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品

Also Published As

Publication number Publication date
MX2007006558A (es) 2007-06-15
JP4968844B2 (ja) 2012-07-04
ATE476200T1 (de) 2010-08-15
EP1819362B1 (en) 2010-08-04
CA2586807A1 (en) 2006-06-08
AU2005311738B2 (en) 2011-02-03
CY1110780T1 (el) 2015-06-10
DE602005022756D1 (de) 2010-09-16
EP1819362A2 (en) 2007-08-22
WO2006060618A3 (en) 2006-10-19
UY29238A1 (es) 2006-05-31
US8324281B2 (en) 2012-12-04
AR052252A1 (es) 2007-03-07
KR20070089687A (ko) 2007-08-31
SI1819362T1 (sl) 2010-10-29
US8071648B2 (en) 2011-12-06
TWI358290B (en) 2012-02-21
JP2012041368A (ja) 2012-03-01
US20120029084A1 (en) 2012-02-02
ES2348249T3 (es) 2010-12-02
PT1819362E (pt) 2010-10-11
TW200626132A (en) 2006-08-01
US7834059B2 (en) 2010-11-16
US20110015271A1 (en) 2011-01-20
BRPI0518904B1 (pt) 2023-01-24
WO2006060618A2 (en) 2006-06-08
HK1104225A1 (en) 2008-01-11
RU2007124638A (ru) 2009-01-10
KR101289661B1 (ko) 2013-07-29
US20060122277A1 (en) 2006-06-08
ZA200704763B (en) 2008-09-25
JP2008521926A (ja) 2008-06-26
DK1819362T3 (da) 2010-10-18
BRPI0518904A2 (pt) 2008-12-16
AU2005311738A1 (en) 2006-06-08
PL1819362T3 (pl) 2010-12-31
CA2586807C (en) 2013-01-29

Similar Documents

Publication Publication Date Title
US8071648B2 (en) Topical nepafenac formulations
JP4968954B2 (ja) 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用
CN1292752C (zh) 含依匹那丁的溶液
JP2016028101A (ja) 非刺激性の眼科用ポビドンヨード組成物
JP2011132259A (ja) コンタクトレンズでの使用に適する眼の抗アレルギー組成物
KR20110032007A (ko) 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물
JP2015110672A (ja) ビマトプロストおよびブリモニジンの固定用量の組み合わせ
EP1906916B1 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
CN1160346A (zh) 用于修复角膜损伤的滴眼液
JP4687837B2 (ja) 眼科用組成物
US20020009507A1 (en) Use of polyethoxylated castor oil for the treatment of dry eye
JP4849288B2 (ja) 点眼剤及び涙液膜の安定化剤
EP1309322B1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
JPWO2001087304A1 (ja) 点眼剤
CN101031310B (zh) 含有黄原胶和氨基酸的眼科用组合物
HK1104225B (en) Topical nepafenac formulations
CN1204961A (zh) 滴眼剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071107